Skip to main content

Management of Severe Hyponatremia and SIADH

  • Chapter
  • First Online:
Evidence-Based Critical Care

Abstract

Severe or acute hyponatremia carries high risk for cerebral edema, seizure and brain death, and requires intensive care unit (ICU) admission and urgent correction. A small immediate correction is sufficient for preventing these neurologic sequelae of hyponatremia. Severe chronic hyponatremia should be evaluated with attention to volume status and treated accordingly. The volume status of an ICU patient can be difficult to assess, and hyponatremia may be multifactorial. Small volume trial of isotonic fluids can be informative in these cases. In all cases of hyponatremia, correction should progress slowly with frequent monitoring of serum sodium. Osmotic demyelination syndrome (ODS) results from overly rapid correction of serum sodium. It can cause devastating paralysis, but newer data suggest that meaningful recovery is often possible. Vasopressin type 2 (V2) receptor antagonists are promising for management of the syndrome of inappropriate antidiuretic hormone activity (SIADH), but the potential for hypovolemia and overly rapid correction of serum sodium in critically ill patients is concerning, and there are no trials specific to ICU settings to guide use. Based on case reports and animal models, urea is an intriguing therapeutic option for correcting serum sodium with reduced risk of ODS, and for preventing ODS in high-risk patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sterns RH, Hix JK, Silver SM. Management of hyponatremia in the ICU. Chest. 2013;144:672–9.

    Article  PubMed  Google Scholar 

  2. Ellison DH, Berl T. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007;356:2064–72.

    Article  CAS  PubMed  Google Scholar 

  3. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007;120:S1–S21.

    Article  CAS  PubMed  Google Scholar 

  4. Sterns RH, Nigwekar SU, Hix JK. The treatment of hyponatremia. Semin Nephrol. 2009;29:196–215.

    Article  Google Scholar 

  5. Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier R, Sterns RH, Thompson CJ. Diagnosis, evaluation and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126:S1–S42.

    Article  PubMed  Google Scholar 

  6. Fenske W, Störk S, Koschker A, Blechschmidt A, Lorenz D, Wortmann S, Allolio B. Value of fractional uric acid excretion in differential diagnosis of hyponatremic patients on diuretics. J Clin Endocrinol Metab. 2008;93:2991–7.

    Google Scholar 

  7. Hato T, Ng R. Diagnostic value of urine sodium concentration in hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion versus hypovolemia. Hawaii Med J. 2010;69:264–7.

    PubMed  PubMed Central  Google Scholar 

  8. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec F, Orlandi C. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–112.

    Article  CAS  PubMed  Google Scholar 

  9. Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA, Smith N. Efficacy and safety of oral conivaptan: a V1/V2a vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006;91:2145–52.

    Article  CAS  PubMed  Google Scholar 

  10. Annane D, Decaux G, Smith N, Conivaptan Study Group. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci. 2009;337:28–36.

    Article  PubMed  Google Scholar 

  11. Decaux G, Andres C, Kengge FG, Soupart A. Treatment of euvolemic hyponatremia in the intensive care unit by urea. Crit Care. 2010;14:R184.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Decaux G, Brimioulle S, Genette F, Mockel J. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by urea. Am J Nephrol. 1980;69:99–106.

    CAS  Google Scholar 

  13. Coussement J, Danguy C, Zouaoui-Boudjeltia K, Defrance P, Bankir L, Biston P, Piagnerelli M. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with urea in critically Ill patients. Am J Nephrol. 2012;35:265–70.

    Article  CAS  PubMed  Google Scholar 

  14. Louis G, Megarbane B, Lavoué S, Lassalle V, Argaud L, Poussel JF, Georges H, Bollaert P. Long-term outcome of patients hospitalized in intensive care units with central or extrapontine myelinolysis. Crit Care Med. 2012;40:970–2.

    Article  PubMed  Google Scholar 

  15. Gankam KF, Soupart A, Pochet R, et al. Re-induction of hyponatremia after rapid overcorrection of hyponatremia reduces mortality in rats. Kidney Int. 2009;76:614–21.

    Article  Google Scholar 

  16. Soupart A, Ngassa M, Decaux G. Therapeutic relowering of the serum sodium in a patient after excessive correction of hyponatremia. Clin Nephrol. 1999;51:383–6.

    CAS  PubMed  Google Scholar 

  17. Oya S, Tsutsumi K, Ueki K, Kirino T. Reinduction of hyponatremia to treat central pontine myelinolysis. Neurology. 2001;57:1931–2.

    Article  CAS  PubMed  Google Scholar 

  18. Sterns RH, Silver SM. Hemodialysis in hyponatremia: is there a risk? Semin Dial Transplant. 1990;3:3–4.

    Article  Google Scholar 

  19. Dhrolia MF, Akhtar SF, Ahmed E, Naqvi A, Rizvi A. Azotemia protects the brain from osmotic demyelination on rapid correction of hyponatremia. Saudi J Kidney Dis Transpl. 2014;25(3):558–66.

    Google Scholar 

  20. Soupart A, Silver S, Schröeder B, Sterns R, Decaux G. Rapid (24-hour) reaccumulation of brain organic osmolytes (particularly myo-inositol in azotemic rats after correction of chronic hyponatremia. J Am Soc Nephrol. 2002;13:1433–41.

    Google Scholar 

  21. Soupart A, Stenuit A, Perier O, Decaux G. Limits of brain tolerance to daily increment in serum sodium in chronically hyponatremic rats treated by hypertonic saline or urea: advantage of urea. Clin Sci. 1991;80:77–84.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Robyn Scatena .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Scatena, R. (2017). Management of Severe Hyponatremia and SIADH. In: Hyzy, R. (eds) Evidence-Based Critical Care. Springer, Cham. https://doi.org/10.1007/978-3-319-43341-7_46

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-43341-7_46

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-43339-4

  • Online ISBN: 978-3-319-43341-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics